The consortium was a collaboration between the Carpenter-Singh Lab, the Genetic Perturbation Platform, and the Center for the Development of Therapeutics at the Broad Institute of MIT and Harvard along with industry and non-profit partners that were committed to creating a public Cell Painting dataset containing both genetic and chemical perturbations. With such a resource, each company or institution can now create its own proprietary Cell Painting data in-house, while matching their profiles against the public set, to guide small molecules’ progression to the clinic.
- Janssen Pharmaceutica NV
- Merck KGaA, Darmstadt, Germany
- Takeda Pharmaceutical Company Limited (“Takeda”)
JUMP also had Collaborators working on this project.